DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Dr - 1 Christopher McGowan - 1 Eli Lilly's - 1 Ozempic - 1 retatrutide - 1 VK2735 - 1 we've - 1
Top related locs:
GLP Mounjaro California
Top related orgs:
Novo Nordisk - 2 Pharma - 1 Viking Therapeutics - 1 Triple - 1 Therapeutics - 1 FDA - 1 orforglipron - 1 Nordisk - 1

Search resuls for: "Eli Lilly's retatrutide"


2 mentions found


☆ 5 new weight-loss drugs to watch in the fight for the next Ozempic
  + stars: | 2024-11-16 | by ( ) www.businessinsider.com   time to read: +8 min
"Forthcoming medications take the blockbuster GLP-1 medications and up the ante." Like semaglutide (the active ingredient in Ozempic and Wegovy), it works on GLP-1, a hormone that regulates blood sugar and appetite. CagriSema adds it to the already-popular drug semaglutide, which itself helps manage hunger and blood sugar levels. "Longer-acting versions of GLP-1 medications offer the potential for greater convenience and potentially improved adherence and sustained use over time," McGowan said. Timeline: Data from Phase II trials is expected later this year, and planning is underway for Phase III trials.
Persons: Eli Lilly, Dr, Christopher McGowan, Eli Lilly's, Ozempic, retatrutide, VK2735, we've, they're, McGowan Organizations: Pharma, Novo Nordisk, Viking Therapeutics, Triple, Therapeutics, FDA, orforglipron, Nordisk, Reuters Locations: GLP, Mounjaro, California
☆ Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
  + stars: | 2023-06-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Eli Lilly ’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday. The trial's researchers said average weight loss did not appear to plateau after 48 weeks, suggesting a longer study could show even more. Eli Lilly’s other obesity drug Mounjaro, which is approved for type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials. Novo Nordisk’ s Wegovy, cleared for weight loss, has shown up to 15% weight loss in trials. But Wegovy only mimics one hunger-regulating hormone called GLP-1, while Mounjaro mimics GLP-1 and another hormone called GIP.
Persons: Eli Lilly ’, Eli Lilly, Eli Lilly’s retatrutide, ” Michael Weintraub, Eli Lilly’s, Eli Lilly's retatrutide Organizations: NYU Langone Health, Novo Nordisk
0 next >>
Total: 2